HC Berlin Pharma AG
Financing of Clinical trials for anti-malarial treatment ArTiMist(TM) secured
HC Berlin Pharma AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Berlin, March 5, 2009 - HC Berlin Pharma AG, a company listed on the Open Market of the Frankfurt Stock Exchange, announces that the financing of the last clinical trial phase of the antimalaria treatment ArTiMist(TM) is secured. Investor is the Corporate Finance company RM Corporate Finance Pty. Ltd. Australia. ArTiMist(TM) is the flagship product of the German pharmaceutical company and its Australian partner company Eastland Medical Systems Ltd., and especially developed for infants and children, which is administered as a sublingual spray. This new method of delivery allows direct access to the blood circulation and shows considerable advantages compared with conventional treatments. 'We are pleased that we can bring ArTiMist(TM) into this phase of the last clinical trials now. We are working together with our Australian partner Eastland Medical Systems Ltd in intensive negotiations with different African states about the realisation of the field studies in their countries and will reach agreements shortly', so Ottmar W. Geiger, CEO of the HC Berlin Pharma AG. 'Now we are getting a big step closer to a quick market entry of ArTiMist(TM)', explains Rudolf W. Schötteldreier, chairman of the board of the HC Berlin Pharma AG. 'In accordance with Eastland Medical Systems Ltd. after the end of the phase III studies we will start to coordinate the marketing', so Schötteldreier finally. Further information on HC Berlin Pharma AG please see www.hcberlinpharma.ag. For detailed information please contact directly our Investor Relations Team: esVedra consulting GmbH t: +49. 89. 28 80 81 33 f: +49. 89. 28 80 81 49 info@esvedra-consulting.com www.esvedra-consulting.com About HC Berlin Pharma AG HC Berlin Pharma AG is a pharmaceutical company listed on the Open Market of the Frankfurt Stock Exchange, which develops and will manufacture pharmaceutical and medical technology solutions at its headquarter in Berlin. The company founded in May 2007 is developing new pharmaceutical forms of already tried and tested substances which guarantee higher efficiency and healing capacity. The flagship product of HC Berlin Pharma AG is ArTiMist(TM), a sublingual spray for malaria treatment, especially designed for infants and children. NiCoSorb(TM), a nicotine replacement therapy is another aerosol spray offered by HC Berlin Pharma AG. In the field of medical technology HC Berlin Pharma AG offers safe injection syringes, ClipOn(TM) and VetLok(TM), for human and veterinary medicine. HC Berlin Pharma AG has also specialized in the production of tamper evident and childproof packaging for remedies. Disclaimer This release only serves general purposes and is by no means intended as an invitation to buy or sell shares of HC Berlin Pharma AG. 05.03.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden